In the talks both ourselves and NHS England continued to offer as much flexibility as possible, but despite the intervention of Secretary of State for Health Wes Streeting, the companies did not put ...

These tools set cookies that store anonymised information about how you got to the site, and how you interact with the site.

Neupulse is a wearable wrist-worn device linked to a mobile phone app, used to treat those over the age of 12. The device delivers low-intensity electrical pulses to the median nerve to reduce tic ...

Discontinued. Please note that following on from information provided to NICE by the company in January 2022, the appraisal was suspended from NICE’s work programme. As no further information has been ...

Are you a pharmaceutical company considering the International Recognition Procedure (IRP) for your UK market entry? While the IRP offers opportunities for faster access to the UK market, it also ...

Suggested remit: To appraise the clinical and cost effectiveness of cabozantinib within its marketing authorisation for treating advanced pancreatic or extra-pancreatic neuroendocrine tumours that ...

According to the study, technologies that received scientific advice took a median of 312 days to progress from marketing ...

NICE did a rapid review of the published literature on the efficacy and safety of this procedure. This comprised a comprehensive literature search and detailed review of the evidence from 8 sources, ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

There is a simple discount patient access scheme for elafibranor. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...